The Trip Report is a podcast and newsletter about the business, science, and policy developments of the evolving psychedelic field. While the main organizing theme is psychedelics, it is really about the many different domains that are converging to bring about this field and the assembly of what many believe to be a “New Paradigm” in science, medicine, and our understanding of the human experience.
In this episode, Zach Haigney speaks with Talia Eisenberg, the co-founder of Beond Ibogaine, because the Beond model – a modern, medical-grade center – seems to me like the closest approximation to what the psychedelic medicine practice of the future will look like.
Ibogaine has developed a reputation as one of the most effective psychedelic substances for the treatment of opioid dependencies, including painkillers, heroin, and fentanyl. Recently, the state of Kentucky’s Opioid Commission announced that it would be evaluating a $42 million grant to study ibogaine for the treatment of opioid addiction and withdrawal.
In this episode, they’ll discuss:
- The history and impact of the opioid epidemic;
- Talia’s personal story of addiction, treatment, and renewal;
- The traditional rehab industry; and
- The importance of short and long-term integration with ibogaine.
